Laboratory assessment of multiple myeloma.


Journal

Advances in clinical chemistry
ISSN: 0065-2423
Titre abrégé: Adv Clin Chem
Pays: United States
ID NLM: 2985173R

Informations de publication

Date de publication:
Historique:
entrez: 25 2 2019
pubmed: 25 2 2019
medline: 2 5 2019
Statut: ppublish

Résumé

Laboratory testing plays an essential role in the diagnosis and management of patients with multiple myeloma. A variety of chemistry and molecular assays are routinely used to monitor patient progress, response to treatment and relapse. Here, we have reviewed current literature and core guidelines on the details of laboratory testing in myeloma-related investigations. This includes the use and value of protein electrophoresis, serum free light chain and cytogenetic testing. Furthermore, we discuss other traditional chemistry assays essential to myeloma investigation, and potential interferences that may arise due to the disease nature of myeloma, that is, the presence of a monoclonal immunoglobulin. Finally, we discuss the importance of communication in protein electrophoresis results, where laboratorians are required to relate clinically relevant myeloma-relevant information to the ordering physician on the background of a complex pattern of serum or urine proteins. Laboratory testing in myeloma-related investigation relies on several traditional chemistry assays. However, we anticipate new tests and technologies to become available in the future with improved analytical sensitivity, as well as improved clinical sensitivity in identifying patients who are at high risk of progression to multiple myeloma.

Identifiants

pubmed: 30797467
pii: S0065-2423(18)30073-8
doi: 10.1016/bs.acc.2018.12.001
pii:
doi:

Substances chimiques

Blood Proteins 0
Immunoglobulins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-58

Informations de copyright

© 2019 Elsevier Inc. All rights reserved.

Auteurs

Tracy Morrison (T)

LifeLabs, Toronto, ON, Canada. Electronic address: tracy.morrison@lifelabs.com.

Ronald A Booth (RA)

Division of Biochemistry, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada.

Kristin Hauff (K)

Interior Health Corporate Office, Kelowna, BC, Canada.

Philip Berardi (P)

Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada; Division of Anatomical Pathology, The Ottawa Hospital/University of Ottawa, Ottawa, ON, Canada.

Alissa Visram (A)

Division of Haematology, The Ottawa Hospital General Campus, Ottawa, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH